
|Articles|January 15, 2004
Prostaglandin analogs help patients stick with regimen
Author(s)Cheryl Guttman
Baltimore-Patients prescribed latanoprost (Xalatan, Pfizer Ophthalmics) continue therapy significantly longer than their counterparts using other prostaglandin-type drugs, according to the results of a population-based, retrospective cohort study.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1
4
Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ
5















































.png)


